Neda Rezvan

Publications (2)1.88 Total impact

• Source

  Available from: Leila Janani

  Article: Elevated serum visfatin levels in patients with acute myocardial infarction.

  Maryam Mazaherioun, Mohammad Javad Hosseinzadeh-Attar, Leila Janani, Ali Vasheghani Farahani, Neda Rezvan, Zohreh Karbaschian, Arash Hossein-Nezhad
  [show abstract] [hide abstract]
  ABSTRACT: Visfatin, a novel adiopocytokine, has been proven to be a proinflammatory mediator involved in the process of atherosclerosis. Visfatin has been shown to play a role in plaque destabilization as it is found abundantly in foam cell macrophages within unstable atherosclerotic plaques. The present study is designed to investigate the potential association between serum vistafin levels and the risk of acute myocardial infarction (AMI). There were 72 patients (mean age: 61.57 ± 11.40 years) as cases who presented with first-time AMI that were assessed 8 hours after the incident. The control group consisted of 83 healthy volunteers (mean age: 60.30 ± 8.32 years). Plasma visfatin levels were measured using enzyme immunoassay in both groups. Biochemical parameters were analyzed. Blood pressure, body mass index (BMI), waist circumference, diabetes, and hypertension were recorded. Serum visfatin levels were significantly higher in patients with AMI (12.77 ± 8.06 ng/ml) compared to controls (6.57 ± 2.96 ng/ml, P ≤ 0.001). We found that a visfatin level > 7.244 ng/ml (log visfatin > 0.86) had a sensitivity of 70% and a specificity of 75% for predicting AMI. We have detected high levels of visfatin in patients with AMI. It can be concluded that proinflammatory cytokines such as visfatin may play a role in the development of atherosclerosis as well as destabilization of the atherosclerotic plaque.
  Archives of Iranian medicine 11/2012; 15(11):688-92. · 0.97 Impact Factor
• Source

  Available from: Leila Janani

  Article: Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy.

  Neda Rezvan, Mohammad Javad Hosseinzadeh-Attar, Farzad Masoudkabir, Ashraf Moini, Leila Janani, Maryam Mazaherioun
  [show abstract] [hide abstract]
  ABSTRACT: There is conflicting data regarding visfatin in gestational diabetes mellitus (GDM). The aim of the present study was to compare serum visfatin levels between patients with GDM and subjects with normal pregnancy and to evaluate its relationship with dietary intake and components of insulin-resistance syndrome. Thirty-five patients with GDM (aged 31 ± 0.8 years, BMI = 29.6) and 35 age- and body mass index-matched healthy pregnant women (aged 29 ± 0.7 years, BMI = 28.6) between 24 and 28 weeks of gestation were studied. In addition to anthropometric and dietary intake assessments, measurements of fasting plasma levels of visfatin, glucose, insulin, hemoglobin A1c (HbA1c) and lipid profile were performed for all subjects. Plasma visfatin levels were significantly lower in pregnant women with GDM compared to healthy subjects (5.29 ± 0.47 vs. 7.76 ± 0.53, p = 0.001). After adjustment for age, maternal gestational age, body mass index, and macronutrients intake, GDM remained the independent predictor of serum visfatin concentrations (β = -1.2, p = 0.001). Serum visfatin levels were significantly correlated with log HbA1c values (r = -0.24, p = 0.03), even after adjustment for age and body mass index (β = -6.45, p = 0.05). No associations between visfatin and other parameters of the insulin-resistance syndrome as well as macronutrient intake were detectable. Plasma visfatin concentrations are lower in patients with GDM and related to glycemic control reflected by HbA1c. Furthermore, visfatin does not seem to be correlated with dietary intake in pregnant women.
  Archives of Gynecology 12/2011; 285(5):1257-62. · 0.91 Impact Factor